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ABSTRACT 
BACKGROUND: The role of the extracellular matrix (ECM) structure and remodeling thereof in 
lung diseases is gaining importance. Pathology-related changes in ECM turnover may result in 
deleterious changes in lung architecture, leading to disease in the small airways. Here, 
degradation fragments of type I (C1M), type IV (αl chain, C4M2), and type IV (α3 chain, C4Ma3) 
collagen, all degraded by metalloproteinases and the pro-form of collagen type V (PRO-C5) were 
investigated and associated with COPD severity and outcome. 
METHODS: In a prospective, observational, multicenter study including 498 patients with COPD 
Gold Initiative for Chronic Obstructive Lung Disease stage 2 to 4, ECM markers were assessed in 
serum at stable state, exacerbation, and at follow-up 4 weeks after exacerbation. 
RESULTS: At stable state, there was a significant inverse association between FEV1 % predicted 
and C1M, C4Ma3, and Pro-C5. C1M, C4M2, C4Ma3, and Pro-C5 were associated with BMI, airflow 
obstruction, dyspnea, and exercise capacity (BODE) index and the modified Medical Research 
Council (MMRC) score. C1M, C4M2, C4Ma3, and Pro-C5 were significantly increased from stable 
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state to exacerbation and decreased at follow-up. Furthermore, the biomarkers were 
significantly higher during severe exacerbation compared with moderate exacerbation. 
Multivariate analysis adjusted for BMI, MMRC score, unadjusted Charlson score, and FEV1 
%predicted showed a significant influence of C1M, C4Ma3, and C4M2 on time to exacerbation. 
None of the biomarkers were predictors for mortality. 
CONCLUSIONS: Serologically assessed collagen remodeling appears to play a significant role in 
COPD severity (airflow limitation, dyspnea) and disease outcome (time to exacerbation and 
prognosis as assessed by the BODE index). 
ABBREVIATIONS: 6MWT = 6-min walk test; ADM = adrenomedullin; BODE = BMI, airflow 
obstruction, dyspnea, and exercise capacity; C1M = type I collagen; C4M2 = type IV alpha-1 
chain; C4Ma3 = type IV alpha-3 chain; ECM = extracellular matrix; GOLD = Gold Initiative for 
Chronic Obstructive Lung Disease; MMP = metalloproteinase; MMRC = modified Medical 
Research Council; Pro-C5 = type V collagen pro-form  
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COPD is characterized by various conditions that result in airflow limitation and an abnormal 
inflammatory response of the lung.1 Inflammation contributes to airflow limitation by causing 
excessive remodeling of the airway wall.2 Lung extracellular matrix consists of cartilage, 
provisional matrix, a basement membrane, and interstitium.3 The basement membrane is 
derived mainly from type IV collagen, which forms the most abundant nonfibrillar collagen in 
the lung.3 The alpha-3 chain of type IV collagen is specific to lung and kidney tissue. It plays an 
important role in cellular proliferation, adhesion, migration, and differentiation. Collagen types I 
and V are fibrillar collagens. Fibrillar collagens allow the lung to maintain its shape during 
inflation and deflation and form 15% to 20% of the dry weight of the lung.3 Collagen types I and 
V are two of the collagens forming the lamina reticularis, which is a thin layer below the 
basement membrane.4,5 Thickening of the lamina reticularis leads to decreased airway 
distensibility and thus increased airway limitation.6 Collagen type V is an autoantigen that plays 
a role in lung transplant rejection and has been shown to correlate to fibrosis. Immunotherapy 
with collagen type V in patients with interstitial pulmonary fibrosis resulted in stabilized FVC7; 
in animals, it resulted in a reduction in lung inflammation and lung fibrosis.8 
We and others have previously demonstrated that collagen degradation is up-regulated in 
patients with COPD9,10 and is associated with some clinically relevant outcomes of COPD.11"13 
Sand et al9 showed that the degradation fragments of collagen types III, IV, and VI are increased 
during exacerbation of COPD compared with follow-up after the exacerbation, but found no 
association between these factors and disease severity. Degradation fragments of collagen type I 
and the formation fragments of collagen type VI are inversely associated with FEV1.14 Collagen 
type I degradation is associated with increased mortality in patients with interstitial pulmonary 
fibrosis15 and in patients with COPD.12 Thus far, no data exist regarding the longitudinal 
expression of the degradation fragments of collagen types I and IV and the formation fragment 
of collagen type V in COPD stable state, exacerbation, and follow-up. We hypothesize that these 
particular collagens are associated with disease severity and outcome in COPD. 
Methods 
STUDY DESIGN AND PATIENTS 
Patients in stable state COPD with Gold Initiative for Chronic Obstructive Lung Disease (GOLD) 2 
to 4 were enrolled in the Predicting Outcome Using Systemic Markers in Severe Exacerbations of 
Chronic Obstructive Pulmonary Disease multicenter trial; an observational prospective trial 
performed in 11 centers in 8 European countries. The study details have been published 
previously.11 The study was investigator-initiated and driven and carried out according to the 
Declaration of Helsinki and Good Clinical Practice guidelines. The institutional review board 
approved the study (EKBB295/07) and it was registered at www.controlled-trials.com 
(identifier ISRCTN99586989). 
Patients were followed for at least 2 years at scheduled half-yearly visits. All participating 
patients had a baseline examination at stable state   and   were   monitored   for   recurrent   
moderate   (requiring 
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treatment with systemic corticosteroids, antibiotics, or both) and severe (requiring 
hospitalization or a visit to the ED) exacerbations. A follow-up visit was performed 4 weeks after 
the onset of exacerbation. Clinical history, physical examination, lung function, and the 6-min 
walk test (6MWT) were performed, and the patients completed the Modified Medical Research 
Council Score (MMRC), the St. George's respiratory questionnaire COPD version, and the 36-item 
Short-Form health survey. The latter is a health-related quality of life questionnaire. The 
evaluation of biomarkers associated with the outcome of the disease was a predetermined end 
point of the study. 
DETERMINATION OF BIOMARKERS 
Serum levels of fragments of collagen type I (C1M), collagen type 4 (αl chain C4M2 and α3 chain 
C4Ma3), and the pro-form of collagen type V (Pro-C5) were measured with Nordic Bioscience 
assays according to the manufacturer's instructions.11,15 All assays used a competitive setup with 
monoclonal antibodies directed against either a protein fragment produced by the 
metalloprotease cleavage during degradation or formation, or an internal protein sequence as 
described previously.15 This means that the assay assesses collagen fragments in which either 
the N- or C-terminal end is known (depending on the assay); therefore, not only one molecular 
size is measured, because the length varies depending on how far upstream or downstream from 
this site it goes. Various fragment lengths were formed depending on how far up- or 
downstream from the N- or C-terminal was measured.10,16 A western blot would most likely 
show a smear of different lengths detected by the antibody. This is a strength of the assay 
because the assay is not limited to detecting only one fragment, which may be undetectable 
because of low concentrations. The choice of the fragments to be assessed was made on the 
basis of previously investigated pathophysiological processes in COPD or data-driven for the 
pioneer discoveries. All samples were analyzed in duplicate by personnel blinded to patients' 
clinical data. 
STATISTICS 
Differences in dichotomous variables were evaluated using the χ2 test or Fisher exact test, as 
appropriate. Normally distributed parameters were analyzed using the Student t test for 
equality of means. All other continuously non-normally distributed parameters were evaluated 
using the nonparametric Mann-Whitney U test or Kruskal-Wallis test, as appropriate. 
The association between the ECM biomarkers and COPD clinical parameters was evaluated by 
univariate linear regression models. Analyses were conducted both unadjusted and adjusted for 
the clinical characteristics such as age, BMI, FEV1 % predicted, MMRC, and unadjusted Charlson 
comorbidity index score at stable state. To predict the risk of exacerbation or death from the 
biomarker values at stable state over time, Cox regression models were performed. 
The Statistical Package for Social Sciences Program (SSPS Inc, version 22, for Windows) was 
used. All tests are two-tailed; a P value < .05 was considered significant. Results are expressed 
as mean (SD) or median (interquartile range), unless otherwise stated. 
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A total of 498 patients were included in the study (Fig 1). The majority of the participants were 
men (72%) and the median age was 67 years (Table 1). 
All collagen biomarkers increased from stable state to exacerbation and then returned to 
baseline levels at follow-up 4 weeks after the exacerbation (Fig 2). C1M median 24.3 vs 41.2 vs 
25.8 ng/mL, C4M2 median was 54.6 vs 65.5 vs 60.2 ng/mL, C4Ma3 median was 5.7 vs 7.2 vs 5.9 
ng/mL, and Pro-C5 median was 469.0 vs 560.1 vs 476.9 ng/mL. 
There were significantly higher levels of the collagen remodeling biomarkers during severe 
exacerbation compared with moderate exacerbation (Fig 3). C1M median was 70.9 vs 31.4 
ng/mL, C4M2 median was 75.6 vs 61.0 ng/mL, C4Ma3 median was 9.3 vs 6.2 ng/mL, and Pro-C5 
median 643.2 vs 450.2 ng/mL. 
COLLAGEN BIOMARKERS AND LUNG FUNCTION 
C1M, C4Ma3, and Pro-C5 were significantly associated to FEV1 % predicted (Table 2) also when 
adjusting for number of severe exacerbations, BMI, smoking status, and unadjusted Charlson 
score. None of the collagen biomarkers were associated with FVC % predicted. All the 
investigated collagen biomarkers showed a significant association with FEV1/FVC % (Table 2). 
There were significant changes in C1M (median, 22.3 ng/mL, 25.3 ng/mL, 27 ng/mL; P = .021); 
C4M2 (median, 53.0 ng/mL, 55.5 ng/mL, 58.6 ng/mL; P = .018); C4Ma3 (median, 5.2 ng/mL, 6.0 
ng/mL, 5.8 ng/mL P = .002), and Pro-C5 (median, 448.6 ng/mL, 488.9 ng/ mL, 474.7 ng/mL; P 
= .009), dependent on the GOLD status (GOLD 2 to 4, respectively) of the patient. 
COLLAGEN BIOMARKERS AND DISEASE EFFECT 
Only C1M was significantly associated with the unadjusted Charlson score (r = 0.106; P = .032), 
but all the biomarkers were highly significantly associated with BMI, airflow obstruction, 
dyspnea, and exercise capacity (BODE) index (Table 3). Both C4Ma3 and Pro-C5 positively 
associated with pack years and in turn negatively associated with the 6MWT. All biomarkers 
were positively associated with MMRC, which represents the degree of dyspnea. There was no 
association between the biomarkers and the various parameters used to determine quality of 
life except between C1M and activity score (r = 0.100; P = .048) as measured using the St. 
George's respiratory questionnaire. 
The biomarker levels did not differ significantly between smokers and nonsmokers. There were 
significant differences in C1M, C4Ma3, and Pro-C5 between patients taking and not taking 
inhaled corticosteroids (ICS) (Table 4). With multiple regression adjusting for the various 
variables that have shown an association with the biomarkers (Table 3), the association 
between the biomarkers and ICS disappeared. 
None of the collagen biomarkers was associated with exacerbation rate or with severe 
exacerbation rate. Cox regression analysis showed that C4Ma3 and Pro-C5 significantly 
influenced time to exacerbation in the first year of follow-up (Fig 4). Lower levels of C4Ma3 (P = 
.05) and Pro-C5 (P = .02) resulted in less time to exacerbation in the first year of follow-up, but 
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this effect disappeared after 2 years. Multivariate Cox regression adjusted for BMI, MMRC score, 
unadjusted Charlson score, and FEV1 % predicted, showed a significant influence of C1M 
(hazard ratio [HR], 1.008; P = .013), C4Ma3 (HR, 0.876; P = .007), and C4M2 (HR, 1.014; P = 
.039) on time to exacerbation in the 2 years of follow-up. 
Figure 1 - Study design. GOLD = Gold Initiative for Chronic Obstructive Lung Disease. 
 
Table 1 -   Basic Characteristics of Patients in the Study 
Characteristic Data 
Men 358 (72) 
Age, y 67 (13) 
Current smoker 144 (29) 
Pack y 45 (35) 
BMI, kg/m2 26 (6.2) 
BODE index 2 (3) 
6MWT, m 398 (120) 
Exacerbation rate 1(0) 
Severe exacerbationrate 0 (0) 
Unadjusted Charlson Score 1(1) 
MMRC score 2(1) 
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Lung function (post-brd)  
 FEV1, L 1.3 (0.7) 
 FVC, L 2.7 (1.2) 
 FEV1, % predicted 50 (27) 
 FVC, % predicted 80 (26) 
GOLD status3  
 II 248 (50) 
 III 168 (34) 
 IV 77 (16) 
Inflammation markers (n = 518)  
 Copeptin, pmol/L 8.5 (12.2) 
 Adrenomedullin, nmol/L 0.6 (0.3) 
 Atrial natriuretic peptide, pmol/L 83.8 (81.2) 
 Procalcitonin, µg/L 0.08 (0.03) 
SF-36  
 Physical function 50 (45) 
 Role physical 50 (100) 
 Role emotional 100 (83) 
 Social functioning 75 (50) 
 Mental health 65 (25) 
 Body pain 80 (48) 
 Vitality 50 (31) 
 General health 50 (37) 
SGRQ  
 Symptoms score 49 (34) 
 Activity score 57 (32) 
 Impact score 29 (27) 
 Total score 39 (27) 
Continuous data are presented as median (interquartile range) and categorical variables as No. (%). 6MWT = 6-min 
walk test; BODE = BMI, airflow obstruction, dyspnea, and exercise capacity; brd = bronchodilator; GOLD = Gold 
Initiative for Chronic Obstructive Lung Disease; MMRC = modified Medical Research Council; SF-36 = 36-item Short-
Form Health Survey; SGRQ = St. George's Respiratory Questionnaire. aG0LD grades are on the basis of FEV1 % 
predicted: 50% ≤ II ≤ 80%; 30% ≤ III ≤ 50%; and IV ≤ 30%. 
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Changes in the turnover of extracellular matrix (ECM) molecules in the lung result in changes in 
lung architecture that may play a role in lung disease. This is the first study to longitudinally 
investigate the role of collagen types I, IV, and V in COPD during stable state, exacerbation, and 
follow-up. We found that the degradation fragments of collagen types I and IV and the collagen V 
formation were increased during exacerbation and decreased to basal levels 4 weeks after 
exacerbation. These molecules were significantly higher during severe exacerbation compared 
with moderate exacerbation. All the collagen biomarkers except for C4M2 were significantly 
negatively associated with FEV1 % predicted. In addition, there was a significant association 
with circulating adrenomedullin, a marker of poor outcome in COPD. 
COPD is associated with changes in airway composition and structure characterized by small 
airway inflammation that results in epithelial damage, airway fibrosis, and remodeling of the 
ECM, affecting both interstitial matrix and basement membrane in the lung.17-19    Whereas 
activated fibroblasts deposit ECM proteins, such as collagens I and III, pathological proteases 
including matrix metalloproteinases (MMPs) 1, 2, 7, 9, and 12 and elastase are overly expressed 
in COPD.20-22 Of interest, FEV1 values were previously found to be inversely correlated with 
collagens in the surface epithelial basement membrane in the lung, suggesting that increased 
bronchial deposition of collagen contributes to deteriorated lung function and airway 
remodeling in COPD. 
The basement membrane, which consists of type IV collagens, functions in anchoring the 
epithelium to the connective tissue as a mechanical barrier and plays a role in angiogenesis. 
Destruction of the basement membrane as suggested by the increase in C4M2 fragments was 
associated with poorer lung function (decrease in FEV1/ FVC), more severe disease (as 
measured by the BODE index), increased dyspnea (as measured by the MMRC score), and an 
increase in the inflammatory marker adrenomedullin (ADM). ADM24 and collagen type IV12 
degradation have been associated with increased mortality in patients with COPD and with 
exacerbation rate. We found no association between collagen type IV degradation and mortality 
or exacerbation rate, but there was an increase in collagen type IV in severe exacerbation 
compared with moderate exacerbation. 
The type IV alpha-3 subunit, although forming part of collagen type IV and thus part of the 
basement membrane, appears to have a phenotype more resembling 
that of collagen type V than the type IV alpha-1 subunit, C4M2. C4Ma3 and Pro-C5 were 
associated with pack years, BODE index, 6MWT, MMRC score, copeptin, ADM, and atrial 
natriuretic peptide. Also, only C4Ma3 and Pro-C5 had a significant effect on time to exacerbation 
in the first year of follow-up. Of interest, no association between C4Ma3 and pack years, 6MWT, 
or MMRC score was found previously9 The discrepancy in results could be because of the small 
population size in the former study9 Not much more is known about C4Ma3 except that 
mutations in the gene encoding this protein result in a disease called Alport syndrome and some 
of the symptoms include dysphagia, recurrent bronchitis, dyspnea, cough, and stridor.25 
Collagen types I and V are two of the collagens forming the lamina reticularis, which forms part 
of the reticular basement membrane.4,5 Thickening of the lamina reticularis, as evidenced in 
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asthma, leads to decreased airway distensibility and thus increased airflow limitation.4,6,20 
Increased ECM turnover, as suggested by the increase in collagen type I fragmentation, had a 
negative association with FEV1; similar to the results by Bihlet et al.14 Unlike Dragsbaek et al26 
and Sand et al,12 we found no association between collagen type I MMP degradation and 
mortality. Collagen type V is an autoantigen that plays a role in lung transplant rejection and has 
been shown to correlate to fibrosis. Immunotherapy with collagen type V in patients with 
interstitial pulmonary fibrosis resulted in stabilized FVC7; in animals, it resulted in a reduction in 
lung inflammation and lung fibrosis.8 We found no association between increased collagen type 
V and FVC, but found a positive correlation with the inflammatory markers copeptin, ADM, and 
atrial natriuretic peptide. 
The relationship between smoking status in COPD and collagen turnover is unclear. One would 
expect that smoking has some influence on the collagen biomarkers because smoking increases 
inflammation, which may drive some of the ECM remodeling through changes in protease 
expression and activity. In line with two previous studies,9,14 we found no association between 
collagen biomarkers and current smoking status. Bihlet et al14 show no significant difference in 
collagen biomarker levels in healthy smokers compared with healthy nonsmokers, nor in 
obstructive, nonemphysematous COPD, and healthy smokers or nonsmokers. Combining 
emphysematous and nonemphysematous COPD shows that collagen VI and elastin degraded by 
neutrophil elastase are significantly higher than in nonsmoking control patients. Collagen I has 
no association with smoking status. Of interest, in the complete COPD group, there are only five 
(9.6%) current smokers. In the smoking group, 12 (48%) are current smokers and the rest are 
ex-smokers. On the one hand, it is unclear whether the difference between the COPD group and 
the nonsmoking group remains if adjusted for other factors such as Charlson Score or FEV1; 
because it is possible that the difference is due to the patients having COPD and not from the 
effects of smoking status. That no difference was seen between healthy smokers and healthy 
nonsmokers gives credence to this assumption. On the other hand, in our study and the study of 
Sand et al,9 most of the COPD nonsmokers were ex-smokers. It is possible that the effects of past 
smoking results in long-term changes in biomarker levels, which because of the occurrence of 
exacerbations, which also affect biomarker levels, are then indistinguishable from the increase 
caused by smoking currently. There is also the possibility that collagen biomarker levels are not 
only driven by inflammation because acute inflammation models in humans and rodents show 
no effect on the markers (J. M. B. Sands, unpublished data, 2018). More studies are required to 
elucidate the relationship between collagen markers and smoking status. 
The severity of the airflow limitation, as assessed by the GOLD classification, was positively 
associated with the levels of the collagen markers. Patients with GOLD 4 had more ECM turnover 
than patients with GOLD 2. This was also evident in patients receiving ICS, who had significantly 
more ECM turnover than the patients not receiving ICS. Although counterintuitive, the increase 
in collagen biomarkers seen in ICS-treated patients is not surprising. Children with asthma 
taking ICS have increased glycosaminoglycans in their urine compared with those on relief 
medication.27 Glycosaminoglycans are proteoglycans forming important structural and 
functional components of the ECM. Priftis et al27 postulated that the increase in urinary 
glycosaminoglycans was due to ICS reversing the remodeling caused by asthma. In asthmatic 
adults, the long-term use of ICS does not decrease the reticular basement membrane thickness 
compared with patients having asthma but not using ICS; unfortunately, the circulating levels of 
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collagen biomarkers were not measured.28 In adult patients with COPD, a 6-month high-dose ICS 
treatment had no effect on hypervascularity or angiogenic growth factors in the reticular 
basement membrane.29 Again, no circulating collagen biomarkers were measured. An in vitro 
study on human lung fibroblasts exposed to 5% fetal calf serum, which mimics the inflammatory 
milieu, showed that budesonide treatment increased ECM and collagen deposition.30 Steroid 
treatment affects collagen levels. It is unclear whether the effect is to reverse the remodeling 
caused by asthma and COPD or whether the effect is to maintain the status quo and thus prevent 
further deterioration. 
Inflammation contributes to airflow limitation by causing remodeling of the airway wall.2 
Collagen types I and IV degradation fragments and type V formation fragments were increased 
during exacerbation, which is characterized by an increase in inflammation. Similarly, it was 
previously shown that during exacerbations of COPD, serum, and urine MMP-9 levels were 
significantly elevated by 17% and 30% compared with recovery values.23 There were relevant 
differences in MMP-8 levels and activity in the different matrices: although serum levels 
depicted unchanged values over a week in patients with stable disease, urine MMPs varied by up 
to ninefold in the same population.23 Results of our study support the notion that the ECM 
derangement resulting in airway remodeling and progressive airflow obstruction at 
exacerbation can be systemically assessed by the determination of circulating fragments of 
collagen degradation and stand in line with a prior study demonstrating higher degradation of 
collagen I and VI in those with a greater loss in lung function over time.31 It is tempting to 
hypothesize that a compound able to prevent collagen degradation, particularly at exacerbation, 
might beneficially influence the vicious cycle of recurrent exacerbations and airflow limitation. 
These markers were higher during severe exacerbation (ie, requiring hospitalization compared 
with mild/ moderate exacerbation). Although collagen types III, IV, and VI are increased during 
exacerbation compared with the follow-up after the exacerbation, this is the first study to 
investigate whether there are differences in collagen biomarkers between severe and 
mild/moderate exacerbations. 
This study has several limitations, including the fact that we did not measure changes in ECM 
markers in stable COPD longitudinally. 
Figure 2 - A, C1M, B, C4M2, C, C4Ma3, and D, Pro-C5 during stable phase (n = 438), exacerbation 
(n = 327), and at follow-up 4 weeks after exacerbation (n = 109). C1M (P < .001), C4M2 (P < 
001), C4Ma3 (P < 001), and Pro-C5 (P < 001) significantly increased from baseline to 
exacerbation and then decreased back to baseline 4 weeks after the exacerbation (follow-up). P 
<05 was considered significant. C1M = Type I collagen; C4M2 = Type IV alpha-1 chain; C4Ma3 
= Type IV alpha-3 chain; Pro-C5 = Type V collagen pro-form. 
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Figure 3 - Boxplot depicting significantly more A, C1M (P < .001); B, C4M2 (P = .040); C, C4Ma3 
(P = .001), and D, Pro-C5 (P < .001) during severe exacerbation (n = 114) than during 
moderate exacerbation (n = 154). P < .05 was considered statistically significant. See Figure 2 
legend for expansion of abbreviations. 
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Table 2 - Univariate Linear Regression of the Association Between Lung Function 
(Postbronchodilator) and the Different Collagens 
Biomarker Beta FEV1, % Predicted Beta FVC, % 
Predicted 
Beta FEV1/FVC, % 
C1M -0.152 0.003 -0.038 0.468 -0.154 0.002 
C4M2 -0.100 0.052 0.022 0.675 -0.144 0.004 
C4Ma3 -0.146 0.005 -0.096 0.063 -0.113 0.026 
Pro-C5 -0.139 0.006 -0.056 0.271 -0.123 0.014 
Boldface type highlights the statistically significant associations. C1M = Type I collagen; C4M2 = Type IV alpha-1 




Table 3 -  Correlation Between Variables and Collagen Markers 
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Age, y 0.078 .117 -0.061 .220 0.054 .273 0.023 .642 
Pack y 0.096 .056 0.073 .145 0.129 .010 0.100 .044 
BMI, kg/m2 -0.044 .372 -0.026 .594 0.036 .469 0.006 .899 
BODE index 0.150 .003 0.152 .003 0.135 .008 0.159 .002 
6MWT, m -0.095 .062 -0.035 .489 -0.100 .048 -0.114 .023 
Exacerbation rate -0.10 .836 -0.023 .645 -0.035 .475 -0.056 .247 
Severe exacerbation rate -0.009 .190 0.049 .323 0.060 .221 0.049 .314 
Unadjusted Charlson Score 0.106 .032 -0.060 .225 0.087 .076 0.076 .118 
MMRC score 0.120 .016 0.113 .023 0.118 .017 0.108 .028 
Lung function (post-brd)         
FEV1, L -0.115 .024 -0.075 .138 -0.081 .110 -0.104 .038 
FVC, L -0.030 .555 0.069 .174 0.009 .866 -0.011 .831 
FEV1, % pred -0.152 .003 -0.100 .052 -0.146 .005 -0.139 .006 
FVC, % pred -0.038 .468 0.022 .675 -0.096 .063 -0.056 .271 
FEV1/FVC -0.154 .002 -0.144 .004 -0.113 .026 -0.123 .014 
Inflammation markers         
Copeptin, pmol/L 0.141 .112 0.070 .156 0.104 .035 0.141 .004 
ADM, nmol/L 0.196 .0001 0.103 .037 0.166 .001 0.196 .0001 
ANP, pmol/L 0.135 .182 0.016 .743 0.124 .012 0.135 .006 
PCT, µg/L 0.054 .436 0.051 .307 0.062 .212 0.054 .271 
Boldface type highlights the statistically significant correlations. ADM = adrenomedullin; ANP = atrial natriuretic 
peptide; PCT = procalcitonin; pred = predicted. See Table 1 and 2 legends for expansion of other abbreviations. 
 
Table 4 -  Comparing the Biomarker Levels (Mean ± SD) in Patients Receiving and Not Receiving ICS 
Biomarker ICS (n = 346) No ICS (n = 77) P 
C1M 34.5 ± 28.0 24.6 ± 11.6 .002 
C4M2 58.8 ± 22.3 53.6 ± 17.2 .110 
C4Ma3 6.3 ± 3.1 5.1 ± 2.2 .002 
Pro-C5 530.7 ± 264.6 435.8 ± 172.4 .004 
Boldface type highlights the statistically significant difference in collagen biomarkers between patients who had 
received ICS and those patients who had not. ICS = inhaled corticosteroids. See Table 2 legend for expansion of other 
abbreviations. 
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Figure 4 - Kaplan-Meier curves showing the significant effect of (A) C4Ma3 (P = .05) and (B) 
Pro-C5 (P = .02) on time to exacerbation. See Figure 2 legend for expansion of abbreviations. 
 
Conclusion 
Collagen degradation and formation may play a significant role in COPD severity (airflow 
limitation, dyspnea) and disease outcome (time to exacerbation, and prognosis as assessed by 
the BODE index). 
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